Health Affairs, 25, no. 5 (2006): 1371-1377 doi: 10.1377/hlthaff.25.5.1371 © 2006 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Figures Only Full Text (HTML) Reprint (PDF) Online Supplemental Exhibits Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Bradford, W. D. Articles by Ornstein, S. Search for Related Content PubMed PubMed Citation Articles by Bradford, W. D. Articles by Ornstein, S. Related Collections Access To Care Ethical Issues Legal/Regulatory Issues Business Of Health Pharmaceuticals Physicians Chronic Care Health Spending Consumer Issues

Health Tracking

MARKETWATCH

How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians’ Prescribing Behavior

Concern about the potential pernicious effect of direct-to-consumer (DTC) drug advertising on physicians’ prescribing patterns was heightened with the 2004 withdrawal of Vioxx, a heavily advertised treatment for osteoarthritis. We examine how DTC advertising has affected physicians’ prescribing behavior for osteoarthritis patients. We analyzed monthly clinical information on fifty-seven primary care practices during 2000–2002, matched to monthly brand-specific advertising data for local and network television. DTC advertising of Vioxx and Celebrex increased the number of osteoarthritis patients seen by physicians each month. DTC advertising of Vioxx increased the likelihood that patients received both Vioxx and Celebrex, but Celebrex ads only affected Vioxx use.

                      What's this?

This article has been cited by other articles:

				B. Parnes, P. C. Smith, C. Gilroy, J. Quintela, C. B. Emsermann, L. M. Dickinson, and J. M. Westfall Lack of Impact of Direct-to-Consumer Advertising on the Physician-Patient Encounter in Primary Care: A SNOCAP Report Ann. Fam. Med, January 1, 2009; 7(1): 41 - 46. [Abstract] [Full Text] [PDF]

				M. R Law, S. R Majumdar, and S. B Soumerai Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study BMJ, September 2, 2008; 337(sep02_1): a1055 - a1055. [Abstract] [Full Text] [PDF]

				J. M. Donohue, M. Cevasco, and M. B. Rosenthal A Decade of Direct-to-Consumer Advertising of Prescription Drugs N. Engl. J. Med., August 16, 2007; 357(7): 673 - 681. [Abstract] [Full Text] [PDF]

				K. C. Stange Time to Ban Direct-to-Consumer Prescription Drug Marketing Ann. Fam. Med, March 1, 2007; 5(2): 101 - 104. [Full Text] [PDF]